Articles tagged with Tau Proteins
Bess Frost, director of Brown University's Center for Alzheimer’s Disease Research, received the 2025 Rainwater Prize for her groundbreaking findings on tau toxicity and retrotransposons. Her work may lead to new treatments for neurodegenerative diseases, including Alzheimer’s and tauopathies.
This study used a senescence-accelerated prone strain 8 (SAMP8) male mice model to observe the protective effects of acupuncture on different brain regions in Alzheimer's disease. Acupuncture treatment improved learning and memory abilities, as well as depression-like behavior, by reducing apoptosis and decreasing tau protein deposition.
Researchers discovered a link between HSV-1 and Alzheimer's disease, suggesting that viral infections play a role in the disease. The study also found that tau protein initially protects the brain from the virus but contributes to brain damage later.
Researchers investigate how perturbed gene expression contributes to neurodegenerative disorders like Alzheimer's. Alternative polyadenylation, a mechanism regulating protein production, is being studied for its potential role in the disease.
Researchers have developed a network-based approach to understand how immune cells called microglia transform and drive harmful processes like neuroinflammation in Alzheimer's disease. The study identified three unique subtypes of harmful microglia that promote disease progression, with genetic signatures driving their behaviors.
Researchers have discovered a specific type of body fat linked to abnormal proteins in the brain that are hallmarks of Alzheimer's disease. Higher levels of visceral fat were found to be associated with increased amyloid accumulation and higher PET levels of hallmark pathologic proteins.
Scientists at Purdue University have identified new molecular markers for neurodegenerative diseases by analyzing protein behavior with age. The study sheds light on how phosphorylation causes protein aggregation, a hallmark of these diseases.
A new review highlights the differences in brain aging and Alzheimer's disease between humans and non-human primates, revealing that primate brains are more resistant to aging-related damage. The study suggests that tau tangles play a critical role in Alzheimer's progression, challenging the amyloid cascade hypothesis.
Researchers at Tel Aviv University discovered a variant of TMEM16F protein that enhances the spread of Parkinson's pathology, potentially leading to new treatments. The study found that cells with the mutation secrete more pathological α-synuclein, which can form Lewy bodies and damage brain cells.
Researchers at Baylor College of Medicine discovered that TYK2 transforms tau into a toxic protein contributing to Alzheimer's disease. Partially restraining TYK2 could be a strategy to reduce tau levels and toxicity.
Researchers at Gladstone Institutes created a new mouse model to study Alzheimer's disease, transplanting human neurons into mouse brains. The study found that immune cells called microglia cause harmful inflammation and clumps of misfolded proteins when interacting with the APOE4 protein.
Researchers have discovered that a glaucoma drug, methazolamide, can clear tau build-up and reduce disease symptoms in zebrafish and mice. The study suggests that carbonic anhydrase inhibitors may be effective in treating neurodegenerative diseases such as Alzheimer's and Parkinson's.
Alzheimer's researchers identify specific inhibitors that prevent nerve cell loss and improve social recognition memory in mouse models. The study sheds light on the molecular sequence of events leading to cellular demise and opens up new research avenues for halting or preventing brain damage.
Researchers validate a new blood test platform that can measure multiple biomarkers of Alzheimer's disease, potentially improving early diagnostics and treatment. The platform captures changes in proteins related to neurodegenerative diseases and may help track disease progression over time.
A recent study found that tau protein buildup disrupts the salience network, a crucial communication network in the brain, leading to behavioral changes. The study used advanced medical imaging to analyze the brains of 128 people with early-stage dementia and showed a strong association between tau disruption and behavioral symptoms.
Researchers have developed a peptide inhibitor called RI-AG03 that effectively prevents Tau protein aggregation in lab and fruit fly studies. The breakthrough targets both major aggregation-promoting 'hotspots' of the Tau protein, potentially paving the way for more effective treatments for neurodegenerative diseases.
Researchers have developed a promising new drug, RI-AG03, that successfully targets and blocks both major aggregation-promoting 'hotspots' of the Tau protein. The peptide-based approach shows significant potential in preventing the build-up of Tau proteins and neurodegeneration, addressing a critical gap in current treatments.
Researchers found that combining APOE4 and TREM2 variants triggers inflammatory response in female brains, damaging brain regions involved in thinking and memory. This study emphasizes the need for tailored approaches to treat Alzheimer's disease differently in men and women.
The Mount Sinai Health System is deploying blood-based biomarkers and confirmatory tests for Alzheimer's disease and related dementias, enabling early detection and intervention. The system aims to stratify patients rapidly, non-invasively, and cost-effectively.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
A study by Baylor College of Medicine researchers reveals that Tau protein mitigates neuronal damage caused by reactive oxygen species and promotes healthy aging. The findings support a new neuroprotective role for Tau against the toxicity associated with ROS.
Researchers genetically engineered Toxoplasma gondii to produce and release therapeutic proteins in the human brain, bypassing the blood-brain barrier. The method has potential implications for treating diseases caused by protein deficiencies or abnormal expression.
Researchers discovered elevated levels of neurofilament light chain protein in Parkinson's disease and dementia with Lewy bodies, suggesting potential early detection methods. The study found different protein patterns between the prodromal stage and established diseases.
Researchers found that combining plasma p-tau217 and Aβ42/40 levels could predict early brain Aβ accumulation in people with subthreshold Aβ accumulation. These biomarkers may help screen participants for primary prevention trials.
Researchers from Jilin University provide a comprehensive overview of brain injury biomarkers, including neuron-specific enolase, ubiquitin C-terminal hydrolase-L1, and neurofilament proteins. These biomarkers can help identify brain injuries and predict disease progression.
Researchers have determined the structure of molecules within an Alzheimer's disease brain for the first time using cryo-electron tomography and fluorescence microscopy. This study revealed the molecular structure of tau protein and its arrangement with amyloid plaques, providing new insights into the pathology of the disease.
Researchers have discovered a new diagnostic method for PSP by analyzing protein biomarkers in spinal fluid, which could lead to earlier diagnosis and targeted therapies. The high-throughput technology allows for the measurement of thousands of proteins in a tiny drop of fluid, providing a promising solution for identifying the condition.
Researchers have developed a new nonhuman primate model that allows for the tracking and treatment of early-stage Alzheimer's disease. The study shows a six-month window in which disease progression can be measured, enabling preclinical testing of interventions targeting the tau protein.
Researchers have developed a blood test that can detect rare forms of dementia, such as frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP), as well as amyotrophic lateral sclerosis (ALS). The test uses biomarkers, including tau and TDP-43 proteins, to identify underlying pathology.
Researchers at Johns Hopkins Medicine identified a potentially new biological target involving Aplp1, which drives the spread of Parkinson's disease-causing alpha-synuclein. The findings suggest targeting this interaction with drugs could slow Parkinson's disease progression and other neurodegenerative diseases.
Researchers used machine learning to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles to identify four distinct molecular profiles of Alzheimer's Disease. These profiles were associated with varying levels of cognitive function and neuropathological features.
Researchers found that boosting mitochondrial health can combat protein clumping linked to both aging and Alzheimer's. The study identifies a core insoluble proteome enriched with numerous proteins not previously considered, offering new targets for exploration.
A new study reveals that people with Down syndrome are more prone to developing Alzheimer's disease due to the presence of an extra chromosome 21, which leads to increased amyloid deposits. As a result, cognitive decline occurs in their 50s, whereas autosomal dominant Alzheimer's typically starts later in life.
A traumatic brain injury quadruples the risk of developing dementia and neurodegenerative diseases like ALS. USC scientists used lab-grown human brain structures called organoids to study TBI's effects. They identified a gene, KCNJ2, that helps protect nerve cells against injury.
Researchers found TDP-43 drives nerve damage after injury and blocking cell surface protein KCNJ2 can correct faulty TDP-43, curbing nerve death. The study provides insights into traumatic brain injury and potential prevention methods.
A new blood test has been shown to diagnose Alzheimer's disease pathology as accurately as FDA-approved spinal fluid tests, making early diagnosis and treatment accessible to more people. The blood test measures levels of Alzheimer's proteins in the blood, detecting molecular signs of the disease even before symptoms appear.
A new blood test uses the biomarker BD-tau to predict functional outcomes in patients after ischemic stroke. Higher levels of BD-tau are associated with more severe outcomes.
Researchers found GV1001 decreases BACE and Aβ1-42 levels, reducing neurodegeneration and senescence in 3xTg-AD mice. It also increases survival, telomere length, and telomerase activity, contributing to improved lifespan.
Researchers connected cognitive and behavioral symptoms to protein buildup in the brain marking the disease. The study showed a clear relationship between CTE pathology and severity of cognitive and functional symptoms during life.
Researchers at Buck Institute for Research on Aging propose an alternate strategy for reversing memory problems in Alzheimer's disease by targeting the KIBRA protein. The findings suggest that KIBRA can rescue mechanisms that promote synapse resilience, potentially leading to improved memory function.
Researchers at Northwestern University have discovered that toxic short RNAs contribute to neuron death and DNA damage in Alzheimer's disease. Studies found that older individuals with superior memories have higher amounts of protective short RNA strands in their brains.
Dutch scientists identified five distinct biological variants of Alzheimer's disease through cerebrospinal fluid proteomics. These variants differ in protein production, immune system function and nerve cell growth, affecting disease progression and treatment responses.
Researchers at the University of Virginia Health System discovered that tau proteins damage brain cells by warping their nuclei, altering gene function and increasing tau production. This finding could lead to new treatments for Alzheimer's disease and other tauopathies.
Researchers found that a rare genetic mutation in the APOE gene, known as the Christchurch mutation, may prevent Alzheimer's dementia by severing the link between amyloid and tau accumulation. This discovery offers new hope for preventing the disease.
Researchers found lower levels of serotonin transporter and higher levels of amyloid-beta protein in brains of people with mild cognitive impairment, a potential target for treatments to slow or stop disease progression. Further research is needed to study the role of serotonin in disease progression.
Researchers investigate whether Tau proteins play a previously unsuspected role in energy management of neurons, potentially leading to new treatment options. The study aims to clarify the role of Tau in energy management and explore novel approaches to develop it into a target for therapies.
Tau protein forms nano-biomolecular condensates that dynamically cluster recycling synaptic vesicles, influencing synaptic function. This study highlights the importance of protein mapping in understanding neural transmission and synaptic plasticity.
A new study has identified specific genes associated with diet and brain structure in kingfishers, which are capable of diving at high speeds. The findings suggest that these birds have evolved unique traits to protect their brains from concussive forces.
A new trial combining an Alzheimer's medication with two other drugs may amplify its effects and arrest disease progression. The trial, funded by a $150M grant, will recruit 900 participants with early-onset Alzheimer's.
Scientists have identified a long non-coding RNA called SNHG8 that plays a crucial role in the development of toxic protein tangles in brain diseases like Alzheimer's. Replacing this RNA can prevent stress granule formation, which contributes to tau aggregation and brain damage.
Researchers identified a link between SARS-CoV-2 infection and Alzheimer's disease-like cognitive symptoms, triggered by Tau protein hyperphosphorylation. The study found increased Tau levels in infected cells, indicating pathological alterations to the protein.
A new blood-based test called p-tau217 has shown great promise in identifying Alzheimer's disease by stratifying patients into low, intermediate, and high-risk groups. The two-step workflow reduces the need for confirmatory testing in uncertain cases.
Researchers found that endogenous retroviruses, naturally present in the human genome, can influence the spread of tau aggregates between cells. This suggests that viral proteins could be potential targets for therapies to stop or slow neurodegeneration.
A new imaging technique, tau PET, has been shown to predict cognitive decline in Alzheimer's patients with greater accuracy than current methods. This breakthrough could lead to earlier diagnosis and treatment, improving patient outcomes.
A study published in Annals of Neurology suggests that a protein in spinal fluid can predict mild cognitive impairment and dementia years before symptoms appear. The findings may offer new targets for treating or preventing Alzheimer's disease and other dementias.
Researchers found that compounds in espresso, such as caffeine and trigonelline, can inhibit tau protein aggregation, a process linked to Alzheimer's. The study suggests potential benefits for neurodegenerative diseases.
The latest Alzheimer's drug, donanemab, has shown encouraging results in slowing cognitive decline by 35% compared to placebo in patients with low-to-intermediate levels of tau. However, its effectiveness is limited for those with more advanced disease, and risks include serious side effects such as amyloid-related imaging abnormalities.
A new biomarker, MTBR-tau243, tracks Alzheimer's disease progression by measuring levels of a specific form of tau in cerebrospinal fluid. The finding has major implications for diagnosing and staging the disease, and could accelerate the development of effective treatments.
ClearTau overcomes limitations of previous methods by producing Tau fibrils efficiently and consistently. This allows researchers to study the development of tauopathies and develop disease-specific therapeutics.
Researchers at Tel Aviv University have developed a novel approach to fight cancer by inducing cancer cells to produce a toxic protein using mRNA molecules. The treatment was successful in eliminating 44-60% of cancer cells in animal models, with no damage to healthy cells.